에소메프라졸 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the esomeprazole market size was valued at USD 2.01 billion in 2025 and estimated to grow from USD 2.13 billion in 2026 to reach USD 2.87 billion by 2031, at a CAGR of 6.08% during the forecast period (2026-2031).

This report is Segmented by Dosage Form (Tablets, Capsules, Others), Strength (20 Mg, 40 Mg, Others), Application (Gastroesophageal Reflux Disease, Stomach Ulcers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Esomeprazole Market Trends and Insights

Increasing Prevalence of GERD

Rising global GERD incidence propels esomeprazole market demand as the disorder now affects up to one fifth of the global population. Direct medical spending in the United States alone reaches USD 9.3 billion annually. Turkey's 23% prevalence mirrors rates in Western economies, while Asia-Pacific sees rising diagnosis given lifestyle shifts and better endoscopic access. Elderly patients face heightened risks of Barrett's esophagus and adenocarcinoma, prompting longer treatment courses. Clinicians thus continue to rely on high-potency proton pump inhibitors, keeping the esomeprazole market on a firm growth footing.

Ageing Population-Linked Gastric Disorders

Demographic aging creates a deeper pool of chronic acid-related diseases that underpin esomeprazole market expansion. Lower esophageal sphincter pressure, reduced saliva flow, and impaired motility worsen reflux in older adults, even when symptoms feel milder. Polypharmacy and comorbidities compound gastric mucosal stress, leading physicians to prefer proven PPIs for long-term control. Payers in developed markets have adjusted formularies to accommodate chronic prescription use, reinforcing esomeprazole market prospects.

Generic Price Erosion & Shrinking Margins

Once key patents lapsed, a wave of approvals for capsules and suspensions drove list prices down by as much as 80%. Major generics players leverage low-cost active ingredient sourcing in India and China, intensifying price competition. Hospital formularies now favor the least-expensive bio-equivalent option, and direct-to-consumer platforms further compress margins, redirecting strategic focus toward volume rather than brand premium.

Other drivers and restraints analyzed in the detailed report include:

1. Rx-to-OTC Switch Momentum in Key Markets
2. Escalating Demand for Pediatric-Approved PPIs
3. Long-Term Safety Concerns

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Tablets controlled 46.12% of the esomeprazole market in 2025 as payers and prescribers gravitated toward the most budget-friendly solid oral form. Capsules, helped by dual-release and nano-delivery technologies, are expected to outpace with a 6.98% CAGR thanks to better nightly symptom control and patient adherence. The esomeprazole market size for tablets is poised to expand steadily, yet capsules will narrow the gap by 2031. Liquid suspensions and intravenous formulations fill specialized gaps in pediatrics and hospitalized acute care.

Capsule makers adopt enteric pellets that release drug in sequential pH zones, offering an immediate and sustained effect that improves mucosal healing rates. Tablet producers defend share with blister-pack redesigns and high-volume cost efficiencies . Hospital procurement committees weigh price ceilings against clinical differentiation, keeping competitive tension strong within the esomeprazole market.

The 20 mg segment held 64.72% of esomeprazole market share in 2025 as it remains the guideline-recommended starting dose for typical GERD. High-dose 40 mg variants are projected to rise at a 6.90% CAGR, supported by clinician experience that dose escalation speeds mucosal healing in refractory cases. The esomeprazole market size for 40 mg is therefore widening faster than its lower-dose counterpart.

Ten-milligram sachets address pediatric weight-based regimens, while combination products such as esomeprazole-domperidone target motility disorders. Strength choice increasingly reflects personalized medicine trends as clinicians calibrate dosing to symptom severity, comorbidities, and nighttime breakthrough episodes.

Complete Report Scope:

• By Dosage Form
  • Tablets
  • Capsules
  • Others
• By Strength
  • 20 mg
  • 40 mg
  • Others
• By Application
  • Gastroesophageal Reflux Disease (GERD)
  • Stomach Ulcers
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America dominated with a 40.12% revenue share in 2025, anchored by GERD awareness programs, wide insurance coverage, and mature generic distribution. The esomeprazole market size in the region will remain substantial through 2031 as aging demographics heighten acid-related morbidity. Europe holds a balanced profile where strong generic uptake meets stringent pharmacovigilance, keeping volumes high but pricing tight.

Asia-Pacific is forecast to register a 7.08% CAGR, the fastest worldwide, driven by rising living standards, urban dietary shifts, and expanded endoscopic services. Local makers have introduced both PPIs and P-CABs, fostering price competition yet also elevating treatment penetration. Emerging regions in Latin America and the Middle East experience rising PPI use as public insurance schemes broaden formulary coverage, though currency volatility and distribution gaps temper upside. Europe maintains a significant market presence through established pharmaceutical manufacturing capabilities and comprehensive healthcare systems that support chronic disease management protocols. The region's regulatory environment promotes generic competition while maintaining quality standards, creating balanced market dynamics between innovation and affordability. Emerging markets in the Middle East and Africa, along with South America, represent growth opportunities driven by healthcare infrastructure development and increasing pharmaceutical access, though market penetration remains constrained by economic factors and regulatory complexities.

1. AstraZeneca
2. Daiichi Sankyo Co. Ltd.
3. Teva Pharmaceutical Industries
4. Sun Pharmaceuticals Industries
5. Dr. Reddy's Laboratories
6. Viatris
7. Cadila Pharmaceuticals Ltd.
8. Torrent Pharmaceuticals
9. Amneal Pharmaceuticals
10. Glenmark Pharmaceuticals
11. Alkem Laboratories Ltd.
12. Aurobindo Pharma Ltd.
13. Lupin
14. Perrigo Company
15. Sandoz (Novartis AG)
16. Takeda Pharmaceuticals
17. Cipla
18. Hikma Pharmaceuticals
19. Pfizer
20. Stada Arzneimittel
21. Haleon Plc

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing prevalence of GERD
  • 4.2.2 Ageing population-linked gastric disorders
  • 4.2.3 Rx-to-OTC switch momentum in key markets
  • 4.2.4 Escalating demand for pediatric-approved PPIs
  • 4.2.5 E-pharmacy penetration in emerging economies
  • 4.2.6 Nano- & dual-release formulation breakthroughs
• 4.3 Market Restraints
  • 4.3.1 Generic price erosion & shrinking margins
  • 4.3.2 Long-term safety concerns
  • 4.3.3 Rapid uptake of P-CAB alternatives
  • 4.3.4 API supply-chain volatility
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Porters Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Dosage Form
  • 5.1.1 Tablets
  • 5.1.2 Capsules
  • 5.1.3 Others
• 5.2 By Strength
  • 5.2.1 20 mg
  • 5.2.2 40 mg
  • 5.2.3 Others
• 5.3 By Application
  • 5.3.1 Gastroesophageal Reflux Disease (GERD)
  • 5.3.2 Stomach Ulcers
  • 5.3.3 Others
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AstraZeneca plc
  • 6.3.2 Daiichi Sankyo Co. Ltd.
  • 6.3.3 Teva Pharmaceutical Industries Ltd.
  • 6.3.4 Sun Pharmaceutical Industries Ltd.
  • 6.3.5 Dr. Reddy's Laboratories Ltd.
  • 6.3.6 Viatris Inc.
  • 6.3.7 Cadila Pharmaceuticals Ltd.
  • 6.3.8 Torrent Pharmaceuticals Ltd.
  • 6.3.9 Amneal Pharmaceuticals LLC
  • 6.3.10 Glenmark Pharmaceuticals Ltd.
  • 6.3.11 Alkem Laboratories Ltd.
  • 6.3.12 Aurobindo Pharma Ltd.
  • 6.3.13 Lupin Ltd.
  • 6.3.14 Perrigo Company plc
  • 6.3.15 Sandoz (Novartis AG)
  • 6.3.16 Takeda Pharmaceutical Co. Ltd.
  • 6.3.17 Cipla Ltd.
  • 6.3.18 Hikma Pharmaceuticals plc
  • 6.3.19 Pfizer Inc.
  • 6.3.20 Stada Arzneimittel AG
  • 6.3.21 Haleon Plc

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment